Dr. Jieer Ying 应杰儿
Chief Physician
Department of Medical Oncology for Hepatobiliary, Pancreatic and Gastric Cancers, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of abdominal malignancies, particularly liver, biliary tract, pancreatic, gastric, and gastrointestinal tumors.
Dr. Ying is Chief Physician and Head of the Department of Hepatobiliary, Pancreatic, and Gastric Oncology at Zhejiang Cancer Hospital. Holding a PhD from Zhejiang University School of Medicine, Dr. Ying began practicing in 1996 and completed training at the Abramson Cancer Center, University of Pennsylvania, in 2010. Research focuses on metastasis mechanisms and targeted therapies.
Name order: in Chinese the family name comes first (Ying Jieer). Papers usually list the name as Jieer Ying or Ying J.
Selected publications
112 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Hepatol, 2026 (senior author): Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: A multicenter, open-label phase II trial. PubMed 42409321
- Clin Exp Med, 2025 (senior author): SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis. PubMed 41217531
- BMC Med, 2025 (senior author): Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers. PubMed 40696434
- Nat Commun, 2025 (senior author): Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial. PubMed 40593475
- Clin Med Insights Oncol, 2024 (senior author): An Active Trend of Immunotherapy Combination Regimen as Second-Line Therapy Towards Advanced Biliary Tract Cancer. PubMed 39421650
- Immun Inflamm Dis, 2024 (senior author): Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy. PubMed 39031507
- Oncologist, 2024 (senior author): Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study. PubMed 38366886
- PeerJ, 2024 (senior author): XYA-2: a marine-derived compound targeting apoptosis and multiple signaling pathways in pancreatic cancer. PubMed 38250721
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion